Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinphar Pharmaceutical CoTPE:1734 -0.16%80 5-Year Yield-on-Cost % is 27.28 as of Aug. 05, 2026, which is 315% above its 10-year median of 6.58. GuruFocus rates TPE:1734 with a GF Score™ of 80/100 and a GF Value™ of NT$31.33 (Fairly Valued). The stock has 1 warning sign investors should review. Among 150 Biotechnology companies, Sinphar Pharmaceutical Co ranks better than 97.33% on this metric.
Sinphar Pharmaceutical Co (TPE:1734) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sinphar Pharmaceutical Co 5-Year Yield-on-Cost % Related Terms
TPE:1734 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's 5-Year Yield-on-Cost % falls into.
Sinphar Pharmaceutical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sinphar Pharmaceutical Co (TPE:1734) has a 5-Year Yield-on-Cost % of 27.28 as of Aug. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sinphar Pharmaceutical Co and its competitors. This is 315% above median its historical median of 6.58. Over the past decade, Sinphar Pharmaceutical Co's 5-Year Yield-on-Cost % has ranged from 1.30 to 29.62. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #4 out of 150 companies in the Biotechnology industry, placing it in the top 2.7%.
Is Sinphar Pharmaceutical Co's 5-Year Yield-on-Cost % too high?
Sinphar Pharmaceutical Co's current 5-Year Yield-on-Cost % of 27.28 is 315% above median its 10-year median of 6.58. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 29.62. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.69. Sinphar Pharmaceutical Co's value of 27.28 is 1514.2% above this industry median. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #4 out of 150 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #4 out of 150 companies for 5-Year Yield-on-Cost %. This places Sinphar Pharmaceutical Co in the top 3% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 1.69. Sinphar Pharmaceutical Co's value of 27.28 is 1514.2% above this benchmark. Historically, Sinphar Pharmaceutical Co's own 5-Year Yield-on-Cost % has ranged from 1.30 to 29.62 over the past decade. While the company's 10-year median is 6.58 vs. the industry median of 1.69, Sinphar Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.69, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinphar Pharmaceutical Co's current 5-Year Yield-on-Cost % of 27.28 is 1514.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sinphar Pharmaceutical Co and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current 5-Year Yield-on-Cost % is 27.28, which is 315% above median its own 10-year median of 6.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.33, compared to a current price of NT$31.70 — trading 1.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 27.28, which is 315% above median its 10-year median of 6.58 and 1514.2% above the Biotechnology industry median of 1.69. Sinphar Pharmaceutical Co's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current 5-Year Yield-on-Cost % is 27.28 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be overvalued.
The current stock price of NT$31.70 is trading 1.2% above its estimated GF Value™ of NT$31.33.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
5-Year Yield-on-Cost %: 27.28 (315% above median its 10-year median of 6.58)
GF Value™: NT$31.33 vs. price of NT$31.70 (1.2% above fair value)
Industry Position: 1514.2% above the Biotechnology median (#4 of 150)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
80GF Score
Get the complete analysis for TPE:1734
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
